Dosing intervals in Comparison of one-year real-world outcomes between red (670 nm) subthreshold micropulse laser treatment and intravitreal aflibercept injection for treatment-naïve diabetic macular edema

•VIVID and VISTA studies used 5 initial monthly loading doses of intravitreal aflibercept injection (IVA), and their results led to the approval of IVA for the treatment of diabetic macular edema (DME) by the United States Food and Drug Administration in 2014.•YOSEMITE and RHINE studies used 5 initial monthly loading doses of IVA in their landmark DME efficacy trials for faricimab.•KESTREL and KITE studies used 5 initial monthly loading doses of IVA in their landmark DME efficacy trials for brolucizumab.